Table 1.
Treatment | Stability of fragile site in indicated categorya |
HPV stabilityb | Reference(s) | |
---|---|---|---|---|
Common | Rare | |||
Aphidicolin | Yes | Yes | Yes | (49, 50) |
ATM dependent | No | No | No, yesb | (51) |
ATR dependent | Yes | Yes | Yes | (51, 52) |
Chk1 dependent | Yes | — | Yes | (53) |
Chk2 dependent | No | — | No | (53) |
Distamycin sensitive | No | Yes | Yes | (19, 54) |
AT-rich DNA | Yes | Yes | Yes | (48) |
Treatment/gene effect on loss of common and rare fragile site stability. —, not reported.
Treatment/gene effect causes loss of HPV episome stability.
cATM siRNA but not ATM inhibitor causes episome loss.